Sutro Biopharma, Inc.
STRO
$39.69
-$1.22-2.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.48M | 105.65M | 104.47M | 66.43M | 62.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.48M | 105.65M | 104.47M | 66.43M | 62.04M |
| Cost of Revenue | 166.42M | 200.81M | 223.07M | 246.76M | 252.04M |
| Gross Profit | -63.93M | -95.17M | -118.59M | -180.33M | -190.00M |
| SG&A Expenses | 41.02M | 41.39M | 46.98M | 49.01M | 48.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 207.44M | 242.20M | 270.04M | 295.77M | 300.50M |
| Operating Income | -104.95M | -136.55M | -165.57M | -229.33M | -238.45M |
| Income Before Tax | -191.19M | -214.43M | -206.36M | -242.85M | -225.10M |
| Income Tax Expenses | -100.00K | 2.34M | 2.34M | 2.36M | 2.36M |
| Earnings from Continuing Operations | -191.09 | -216.77 | -208.70 | -245.22 | -227.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.09M | -216.77M | -208.70M | -245.22M | -227.46M |
| EBIT | -104.95M | -136.55M | -165.57M | -229.33M | -238.45M |
| EBITDA | -97.63M | -128.99M | -158.10M | -221.98M | -231.24M |
| EPS Basic | -22.55 | -25.76 | -25.00 | -29.56 | -29.89 |
| Normalized Basic EPS | -10.14 | -12.27 | -14.31 | -18.89 | -21.05 |
| EPS Diluted | -22.55 | -25.76 | -25.00 | -29.56 | -29.89 |
| Normalized Diluted EPS | -10.14 | -12.27 | -14.31 | -18.89 | -21.05 |
| Average Basic Shares Outstanding | 33.99M | 33.72M | 33.44M | 33.10M | 30.94M |
| Average Diluted Shares Outstanding | 33.99M | 33.72M | 33.44M | 33.10M | 30.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |